International Journal of Pharmaceutics, 37 (1987) 265–266
Elsevier

Author Index

Abra, R.M., see Schreier, H., 233
Ahlgren, R., see Nicklasson, M., 195
Al-Angary, A.A., see Gouda, M.W., 227
Alderborn, G., Lång, P.O., Sågström, A. and Kristensen, A., Compression characteristics of granulated materials. I. Fragmentation propensity and compactability of some granulations of a high dosage drug, 155
Atsumi, R., see Takakura, Y., 145

Babhair, S.A., see Gouda, M.W., 227
Bialer, M., see Hussein, Z., 97
Bonfils, A., see Heyman, M., 33
Bourne, D.W.A., see Kwon, K., 219
Brophy, M.R. and Deasy, P.B., Application of the Higuchi model for drug release from dispersed matrices to particles of general shape, 41
Bundgaard, H. and Buur, A., Prodrugs as drug delivery systems. 65. Hydrolysis of α-hydroxy- and α-acyloxy-*N*-benzoylglycine derivatives and implications for the design of prodrugs of NH-acidic compounds, 185
Bundgaard, H., see Larsen, J.D., 87
Buur, A., see Bundgaard, H., 185

Camber, O. and Edman, P., Factors influencing the corneal permeability of prostaglandin $F_{2\alpha}$ and its isopropyl ester in vitro, 27
Casabó, V.G., see Plá-Delfina, J.M., 49
Castaño, A., see Navarro, A.S., 113
Chiang, C.-M. and Weiner, N., Gastrointestinal uptake of liposomes. I. In vitro and in situ studies, 75
Clark, A.G., see Hardy, J.G., 245
Crain-Denoyelle, A.M., see Heyman, M., 33
Crommelin, D.J.A., see Talsma, H., 171

Darbord, J.-C. and Laizier, J., A theoretical basis for choosing the dose in radiation sterilization of medical supplies, 1
Deasy, P.B., see Brophy, M.R., 41
Dechesne, J.-P., A new enteric tablet of acetylsalicylic acid. I. Technological aspects, 203
Desjeux, J.F., see Heyman, M., 33
Djurić, M., Jovanović, M. and Djurić, Z., Influence of drug amount and dioctyl sodium sulfosuccinate on dissolution of propyphenazone tablets, 179
Djurić, Z., see Djurić, M., 179
Dominguez-Gil Hurlé, A., see Navarro, A.S., 113

Edman, P., see Camber, O., 27
Edwards, H.E., see Menzies, A.R., 65

El-Hinnawi, M.A. and Najib, N.M., Ibuprofen–polyvinylpyrrolidone dispersions. Proton nuclear magnetic resonance and infrared studies, 175
El-Hofy, S.A., see Gouda, M.W., 227
Evans, D.F., see Hardy, J.G., 245

Fassihi, A.R., Kinetics of drug release from solid matrices: effect of compaction pressure, 119
Fassihi, A.R. and Persicaner, P.H.R., Solid state interaction of bromazepam with polyvinylpyrrolidone in the presence of moisture, 167
Fawzi, M.B., see Ghebre-Sellassie, I., 211
Fortier, M., see Heyman, M., 33
Friedman, M., see Hussein, Z., 97

Gamst, O.N., see Hardy, J.G., 245
Ghebre-Sellassie, I., Gordon, R.H., Nesbitt, R.U. and Fawzi, M.B., Evaluation of acrylic-based modified-release film coatings, 211
Gordon, R.H., see Ghebre-Sellassie, I., 211
Gouda, M.W., Babhair, S.A., Al-Angary, A.A., El-Hofy, S.A. and Mahrous, G.M., Effect of dosage form, food, and an anticholinergic drug on the bioavailability of sulpiride, 227
Green, P.G. and Hadgraft, J., Facilitated transfer of cationic drugs across a lipoidal membrane by oleic acid and lauric acid, 251

Hadgraft, J., see Green, P.G., 251
Hardy, J.G., Evans, D.F., Zaki, I., Clark, A.G., Tønnesen, H.H. and Gamst, O.N., Evaluation of an enteric coated naproxen tablet using gamma scintigraphy and pH monitoring, 245
Hashida, M., see Takakura, Y., 135
Hashida, M., see Takakura, Y., 145
Heyman, M., Bonfils, A., Fortier, M., Crain-Denoyelle, A.M., Smets, P. and Desjeux, J.F., Intestinal absorption of RU 41710, an immunomodulating compound extracted from *Klebsiella pneumoniae*, across duodenal epithelium and Preyer's patches of the rabbit, 33
Hunt, C.A., see Schreier, H., 233
Hussein, Z., Bialer, M., Friedman, M. and Raz, I., Comparative pharmacokinetic evaluation of sustained-release theophylline formulations in dogs and humans, 97

Ikeda, C., see Yamaguchi, T., 127
Ismail, S. and Morton, D.J., Ophthalmic uptake of chloramphenicol from proprietary preparations using an in vitro method of evaluation, 11

0378-5173/87/$03.50 © 1987 Elsevier Science Publishers B.V. (Biomedical Division)

Jousma, H., see Talsma, H., 171
Jovanović, M., see Djurić, M., 179

Kaplan, J.E., see Schreier, H., 233
Karjalainen, P., see Vidgren, M.T., 239
Kitajima, M., see Takakura, Y., 135
Kristensen, A., see Alderborn, G., 155
Kwon, K. and Bourne, D.W.A., Physiological pharmacokinetic model for the distribution and elimination of tenoxicam, 219
Kärkkäinen, A., see Vidgren, M.T., 239

Laizier, J., see Darbord, J.C., 1
Lanao, J.M., see Navarro, A.S., 113
Lång, P.O., see Alderborn, G., 155
Larsen, J.D. and Bundgaard, H., Prodrug forms for the sulfonamide group. I. Evaluation of *N*-acyl derivatives, *N*-sulfonylamidines, *N*-sulfonyl sulfilimines and sulfonylureas as possible prodrug derivatives, 87
Lindberg, J., see Nicklasson, M., 195

Macheras, P. and Reppas, C., Dissolution and in vitro permeation behaviours of dicumarol nitrofurantoin and sulfamethizole in the presence of protein, 103
Mahrous, G.M., see Gouda, M.W., 227
Martín-Villodre, A., see Plá-Delfina, J.M., 49
Matsumoto, S., see Takakura, Y., 135
Menzies, A.R. and Edwards, H.E., Some of the biological properties of factor X-fractionated heparin, 65
Mikkelson, T.J., see Mitra, A.K., 19
Mitra, A.K. and Mikkelson, T.J., Ophthalmic solution buffer systems. II. Effects of buffer type and concentration on the ocular absorption of pilocarpine and a method of ocular bioavailability prediction from physicochemical data, 19
Morton, D.J., see Ismail, S., 11

Najib, N.M., see El-Hinnawi, M.A., 175
Navarro, A.S., Castaño, A., Lanao, J.M. and Dominguez-Gil Hurlé, A., In vitro interaction between HAPA-gentamicin B and penicillins, 113
Nesbitt, R.U., see Ghebre-Sellassie, I., 211
Nicklasson, M., Wennergren, B., Lindberg, J., Persson, C., Ahlgren, R., Palm, B., Pettersson, A. and Wenngren, L., A collaborative in vitro dissolution study using the flow-through method, 195
Nicolay, K., see Talsma, H., 171

Palm, B., see Nicklasson, M., 195
Paronen, T.P., see Vidgren, M.T., 239
Peris-Ribera, J.E., see Plá-Delfina, J.M., 49
Persicaner, P.H.R., see Fassihi, A.R., 167
Persson, C., see Nicklasson, M., 195
Pettersson, A., see Nicklasson, M., 195
Plá-Delfina, J.M., Pérez Buendia, M.D., Casabó, V.G., Peris-Ribera, J.E., Sánchez-Moyano, E. and Martín-Villodre, A., Absorption–partition relationships for true homologous series of xenobiotics as a possible approach to study mechanisms of surfactants in absorption, 49
Pérez Buendía, M.D., see Plá-Delfina, J.M., 49

Raz, I., see Hussein, Z., 97
Reppas, C., see Macheras, P., 103
Riley, C.M., see Stout, S.A., 257
Roberts, R.J. and Rowe, R.C., The Young's modulus of pharmaceutical materials, 15
Rowe, R.C., see Roberts, R.J., 15

Sågström, A., see Alderborn, G., 155
Schreier, H., Abra, R.M., Kaplan, J.E. and Hunt, C.A., Murine plasma fibronectin depletion after intravenous injection of liposomes, 233
Sekine, Y., see Yamaguchi, T., 127
Sezaki, H., see Takakura, Y., 135
Sezaki, H., see Takakura, Y., 145
Smets, P., see Heyman, M., 33
Stout, S.A. and Riley, C.M., Hydrolysis of L-phenylalanine mustard (melphalan). II. Further observations on the effects of pH, chloride ions and buffers on the rate of reaction, 257
Svensson, C.K., Effect of single and short-term multiple exposure to honeybee venom on the disposition of antipyrine in the rat, 163
Sánchez-Moyano, E., see Plá-Delfina, J.M., 49

Takakura, Y., Kitajima, M., Matsumoto, S., Hashida, M. and Sezaki, H., Development of a novel polymeric prodrug of mitomycin C, mitomycin C–dextran conjugate with anionic charge. I. Physicochemical characteristics and in vivo and in vitro antitumor activities, 135
Takakura, Y., Atsumi, R., Hashida, M. and Sezaki, H., Development of a novel polymeric prodrug of mitomycin C, mitomycin C–dextran conjugate with anionic charge. II. Disposition and pharmacokinetics following intravenous and intramuscular administration, 145
Talsma, H., Jousma, H., Nicolay, K. and Crommelin, D.J.A., Multilamellar or multivesicular vesicles? 171
Tønnesen, H.H., see Hardy, J.G., 245

Vidgren, M.T., Kärkkäinen, A., Karjalainen, P. and Paronen, T.P., A novel labelling method for measuring the deposition of drug particles in the respiratory tract, 239

Weiner, N., see Chiang, C.-M., 75
Wennergren, B., see Nicklasson, M., 195
Wenngren, L., see Nicklasson, M., 195

Yamaguchi, T., Ikeda, C. and Sekine, Y., Intestinal absorption of a β-adrenergic blocking agent nadolol. Enhancement of in situ and in vivo absorption of nadolol in rats, 127

Zaki, I., see Hardy, J.G., 245